FDA Recalls Thyroid Tablets for Superpotency: Lot Number, Symptoms and Patient Advice
FDA Thyroid Tablet Recall 2026 affects Vitruvias Thyroid Tablets, USP 30 mg, lot 504950, due to potential superpotency. Learn how to identify the recalled medicine, recognise excess thyroid hormone symptoms, understand urgent warning signs and obtain a safe replacement without stopping treatment independently.